Protein kinase inhibitors erlotinib (OSI-774; Tarceva), everolimus (RAD001; Afinitor), and sumitinib (SU11248; Sutent) are approved for the treatment of pancreatic cancers [4], though the majority of these approvals are for a rare (1% to 2%) subtype of pancreatic cancer known as pancreatic neuroendocrine tumors [6] rather than the far more common PDAC. Here, WEE1 is linked to familial pancreatic carcinoma.